Compare FINW & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | PLYX |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.7M | 271.8M |
| IPO Year | 2021 | N/A |
| Metric | FINW | PLYX |
|---|---|---|
| Price | $14.50 | $3.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 20.8K | ★ 302.5K |
| Earning Date | 04-30-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.51 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $160.48 | N/A |
| Revenue Next Year | $35.27 | N/A |
| P/E Ratio | $72.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.82 | $2.07 |
| 52 Week High | $22.49 | $9.18 |
| Indicator | FINW | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 45.42 |
| Support Level | $12.82 | $2.58 |
| Resistance Level | $17.39 | $7.29 |
| Average True Range (ATR) | 0.49 | 0.63 |
| MACD | 0.20 | 0.04 |
| Stochastic Oscillator | 93.01 | 63.23 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.